http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130529:nBw296261a
   
  http://www.businesswire.com/news/home/20130529006261/en
   ELMWOOD PARK, N.J. & NEW YORK--(Business Wire)--The Regulatory Harmonization Institute, Inc. (RHI), an international,not-for-profit association dedicated to global harmonization of drug and medicaldevice regulatory requirements, recently presented an educational seminar forthe U.S.- Japan Health Care Study Group, which was held in New York City.Entitled "Lessons Learned in Algeria/North Africa: Workshops, Presentations andGap Analysis," the program drew representatives from leading Japanesepharmaceutical manufacturers and focused uponemerging markets for sales,solidifying market share, and bringing product to an expanding customer base. Dean Erhardt, president of RHI says, "Robust growth in the pharmaceuticalmarkets of emerging world economies has outpaced the overall growth of theglobal pharmaceutical market, and accounts for the heightened interest amongcompanies in developed nations such as Japan. Current estimates have as much as90 percent-or $165 billion over the next five years-of future pharmaceuticalgrowth coming from the emerging economies of China, India, Brazil, Mexico, andother regions of the world.* RHI shared its experience in Algiers where the organization is conductingeducational forums on regulatory approval processes. Joseph Carabello, RHI founder, explains, "Collectively, the emerging markets arereshaping the pharmaceutical marketplace, and undoubtedly offer high potential,with rising GDPs, large and growing populations with increased access tohealthcare, and an improving IP and regulatory environment." RHI, the only organization whose mission is solely focused on matters related toregulatory harmonization, is supported by members that include governmentagencies, public and private companies, patient advocacy groups, not-for-profitorganizations, academic professionals and other industry groups. In addition toits educational programs, RHI also generates government and private sectorsupport for information exchange, product development, and investment. RHI activities focus upon:           1.    Reducing the overall cost to bring products to market, assisting in maintaining viable manufacturer margins which can be invested in ongoing research for innovative drug therapies.                    2.    Reducing the drug lags from country to country, enabling unique innovator products to access new markets quicker and resulting in more innovative therapies being available to more patients.           3.    Creating a reduced timeline to get less expensive products -- generics and biosimilars -- to new markets, assisting financially strapped governments in keeping down the cost of therapies.      About Regulatory Harmonization Institute:Regulatory Harmonization Institute, Inc. (RHI) is a non-profit associationdedicated to global harmonization of regulatory requirements with a mission toinfluence the development and introduction of meaningful therapies to patientsacross the globe. RHI will advance global harmonization of regulatoryrequirements for medicines and devices intended for human use, enabling greaterdelivery of meaningful new therapies to all patient populations. Visithttps://
  www.regharmonization.com.
   CPR Communications for RHIKatelyn Petersen, 201-641-1911 x18kpetersen@cpronline.comCopyright Business Wire 2013